Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm?

被引：2
|
作者：
Pusceddu, S. [1 ]
Buzzoni, R. [2 ]
De Braud, F. [1 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan ENETS Ctr Excellence, Med Oncol Unit, Milan, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Milan ENETS Ctr Excellence, Day Hosp Outpatient Unit, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2013年 / 24卷 / 05期
关键词：
TUMORS;
D O I：
10.1093/annonc/mdt102
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1415 / 1416
页数：3
相关论文
共 8 条
  • [1] Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumors Resistant to Prior Treatments
    Angelousi, A.
    Kampel, K.
    O'Toole, D.
    Kaltsatoy, M.
    Boutzios, G.
    Alexandraki, K.
    Kaltsas, G.
    De Herder, W.
    [J]. NEUROENDOCRINOLOGY, 2016, 103 : 77 - 77
  • [2] Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments
    Angelousi, Anna
    Kamp, Kimberly
    Kaltsatou, Maria
    O'Toole, Dermot
    Kaltsas, Gregory
    de Herder, Wouter
    [J]. NEUROENDOCRINOLOGY, 2017, 105 (04) : 394 - 402
  • [3] RESPONSE EVALUATION USING RECIST AND CHOI CRITERIA IN PATIENTS WITH WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS (PNET) TREATED WITH SUNITINIB OR EVEROLIMUS
    Dreyer, C.
    Hentic, O.
    Zappa, M.
    Hammel, P.
    Bouattour, M.
    Mateescu, C.
    Faivre, S.
    Ruszniewski, P.
    Raymond, E.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 379 - 379
  • [4] Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus
    Hentic, Olivia
    Dreyer, Chantal
    Zappa, Magaly
    Hammel, Pascal
    Mateescu, Cristian
    Bouattour, Mohamed
    Faivre, Sandrine J.
    Ruszniewski, Philippe
    Raymond, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Clinical Study on High-Risk Factors Leading to Recurrence of Well-Differentiated Pancreatic Neuroendocrine Neoplasms after Surgery
    Zhang, P.
    Li, Y. L.
    Qiu, X. D.
    Luo, J.
    Tan, H. Y.
    [J]. NEUROENDOCRINOLOGY, 2018, 106 : 131 - 131
  • [6] ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors
    Falconi, Massimo
    Bartsch, Detlef Klaus
    Eriksson, Barbro
    Kloeppel, Guenter
    Lopes, Jose M.
    O'Connor, Juan M.
    Salazar, Ramon
    Taal, Babs G.
    Vullierme, Marie Pierre
    O'Toole, Dermot
    [J]. NEUROENDOCRINOLOGY, 2012, 95 (02) : 120 - 134
  • [7] Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN).
    Dreyer, Chantal
    Couvelard, Anne
    Walter, Thomas
    Bohas, Catherine Lombard
    Niccoli, Patricia
    Seitz, Jean-Francois
    Hentic, Olivia
    Pellat, Anna
    Andre, Thierry
    Couffignat, Camille
    Lobbe, Nathalie
    Mentre, France
    Bedossa, Pierre
    Hammel, Pascal
    Faivre, Sandrine J.
    Zappa, Magalie
    Ruszniewski, Philippe B.
    Raymond, Eric
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [8] Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study
    Ito, Tetsuhide
    Tori, Masayuki
    Hashigaki, Satoshi
    Kimura, Nobuyuki
    Sato, Kazuo
    Ohki, Emiko
    Sawaki, Akira
    Okusaka, Takuji
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (04) : 354 - 360
1